BINV — BioInvent International AB Share News
0.000.00%
Last trade - 00:00- SEK1.33bn
- SEK1.01bn
- SEK226.50m
Brief: CASI Pharmaceuticals Partner, Bioinvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin's Lymphoma Patients
Brief: Bioinvent: Positive Interim Results From The Phase I/IIa Trial
Brief: Transgene, Bioinvent Get ANSM Approval For Phase I/IIa Trial
Brief: Bioinvent Streamlines Agreement On Anti-Fcγrllb Antibody
Brief: Bioinvent Receives $3 Mln Payment Related To Selection Of Antibodies Under Collaboration With Pfizer
Brief: Transgene And Bioinvent Receive CTA Approval For Phase 1/2A Trial Of Oncolytic Virus BT-001 In Solid Tumors
Brief: Bioinvent And Cantargia Sign Manufacturing Agreement For Monoclonal Antibody CAN10
Brief: BioInvent Q3 Loss After Tax Narrows To SEK 32.9 Million
CASI Pharma: Rises on deal with BioInvent to develop, market cancer drug
Brief: BioInvent Gets EUR 2 Mln Milestone Payment From Daiichi Sankyo
Brief: BioInvent Q2 Loss After Tax Widens To SEK 39.3 Mln
Brief: Bioinvent Sek 139 Million Rights Issue Heavily Oversubscribed
Brief: BioInvent International: BI-1206 Could Improve Treatment In Several Cancers
Brief: Bioinvent to launch SEK 139 mln repair rights issue
Brief: Finansinspektionen Says Van Herk Investments B.V. Increases Stake In Bioinvent
Brief: Bioinvent International Extends Research Collaboration And License Agreement With Pfizer Inc.
Swedish stocks: Seen opening slightly higher
Brief: BioInvent Successfully Completes Directed Share Issue Of About SEK 487 Mln
Brief: Bioinvent Enters New Production Deal With American Company